Cognitive Heterogeneity in Alzheimer Clinical Trials
Harnessing Noise to Achieve Meaningfulness
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published May 31, 2021.
Author Disclosures
- Rachel F. Buckley, PhD and
- David S. Knopman, MD
- Rachel F. Buckley, PhD and
NONE
NONE
NONE
Journal of Alzheimer's Disease (2 years: 2014-2016) Special editor of Alzheimer's & Dementia DADM sub-journal (2020-2021) Editorial Board of Neurology (2020-)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NHMRC Dementia Research Fellowship, APP1105576, CIA, 2016-2020 NIH-NIA K99/R00 Pathway to Independence award: 2020- 2024
NONE
Alzheimer's Association Research Fellowship (2020- 2023)
NONE
NONE
NONE
NONE
NONE
NONE
- David S. Knopman, MD
DIAN study DSMB (Sept 2013 - July 2019; August 2020 - present).
NONE
NONE
Omsbudsman Neurology, previously; Scientific Integrity officer, currently
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) A4 clinical trial partially funded by Lilly (site PI) (2) Biogen Alzheimer Study (site PI)
NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo AlzheimerÂs Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (R.F.B.), Massachusetts General Hospital and Harvard Medical School; Center for Alzheimer Research and Treatment (R.F.B.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; Melbourne School of Psychological Science (R.F.B.), University of Melbourne, VIC, Australia; and Department of Neurology (D.K.), Mayo Clinic, Rochester, MN.
- Correspondence
Dr. Buckley rfbuckley{at}mgh.harvard.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Alzheimer disease brain atrophy subtypes are associated with cognition and rate of declineShannon L. Risacher, Wesley H. Anderson, Arnaud Charil et al.Neurology, October 25, 2017 -
Article
Randomized controlled trials in mild cognitive impairmentSources of variabilityRonald C. Petersen, Ronald G. Thomas, Paul S. Aisen et al.Neurology, April 05, 2017 -
Article
Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression HeterogeneityRoos J. Jutten, Sietske A.M. Sikkes, Wiesje M. Van der Flier et al.Neurology, May 31, 2021 -
Article
Determining clinically meaningful decline in preclinical Alzheimer diseasePhilip S. Insel, Michael Weiner, R. Scott Mackin et al.Neurology, July 09, 2019